Rayon Gene: Sales of two newer products are growing rapidly, rapidly opening up the market.

On the evening of May 25th, RegenGene issued a announcement in response to the information disclosure supervision inquiry letter regarding the 2025 annual report. The announcement stated that RegenGene's two relatively new products, the "Leukemia-related 15 fusion gene detection kit" and the "BCR-ABL P210 fusion gene detection kit," are currently in the rapid market introduction stage, with a significant increase in new hospital clients in 2025 and a rapid growth in sales volume.